Biointron, a Chinese contract research organisation (CRO) that serves life science researchers and biopharmaceutical companies, has secured almost 500 million yuan ($72.4 million) in a Series B funding round to expand its operations.
Access this premium content with a DATA VANTAGE subscriptionLearn more about DATA VANTAGE
Already a Subscriber? Log in
Contact us for corporate subscriptions at firstname.lastname@example.org